Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay

Matthew J. Murray,Megan McIntosh,Claire Atkinson, Tabitha Mahungu,Edward Wright,Wendy Chatterton,Michael Gandy,Matthew B. Reeves

Journal of Infection（2021）

引用 24|浏览4

暂无评分

摘要

•An ELISA based cPass assay provides a measure of Spike RBD binding antibodies.•Binding in a cPass ELISA correlates strongly with pseudotyped virus neutralisation.•ELISA-based surrogate assays provide rapid data on neutralising capacity.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要